BHVN Biohaven Ltd.

NYSE biohavenpharma.com


$ 7.88 $ 0.00 (0 %)    

Wednesday, 12-Nov-2025 06:30:52 EST
QQQ $ 624.39 $ 0.00 (0 %)
DIA $ 480.14 $ 0.00 (0 %)
SPY $ 684.61 $ 0.00 (0 %)
TLT $ 89.65 $ 0.00 (0 %)
GLD $ 379.71 $ 0.00 (0 %)
$ 8.52
$ 7.73
$ 7.78 x 10
$ 7.87 x 76
-- - --
$ 7.48 - $ 52.76
5,873,663
na
580.73M
$ 1.96
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-10-2025 09-30-2025 10-Q
2 08-11-2025 06-30-2025 10-Q
3 05-12-2025 03-31-2025 10-Q
4 03-03-2025 01-01-1970 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-09-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 02-29-2024 12-31-2023 10-K
9 11-14-2023 09-30-2023 10-Q
10 07-31-2023 06-30-2023 10-Q
11 05-12-2023 03-31-2023 10-Q
12 03-23-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 biohaven-announces-150m-common-stock-offering

Biohaven Ltd. (NYSE:BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commerci...

 bernstein-downgrades-biohaven-to-market-perform-lowers-price-target-to-9

Bernstein analyst William Pickering downgrades Biohaven (NYSE:BHVN) from Outperform to Market Perform and lowers the price t...

 rbc-capital-maintains-sector-perform-on-biohaven-lowers-price-target-to-9

RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Sector Perform and lowers the price target from $1...

 btig-maintains-buy-on-biohaven-lowers-price-target-to-16

BTIG analyst Thomas Shrader maintains Biohaven (NYSE:BHVN) with a Buy and lowers the price target from $33 to $16.

 william-blair-downgrades-biohaven-to-market-perform

William Blair analyst Myles Minter downgrades Biohaven (NYSE:BHVN) from Outperform to Market Perform.

 td-cowen-maintains-buy-on-biohaven-lowers-price-target-to-15

TD Cowen analyst Tyler Van Buren maintains Biohaven (NYSE:BHVN) with a Buy and lowers the price target from $50 to $15.

 biohaven-stock-hits-52-week-low-cuts-rd-spending-after-fda-rejection

Biohaven stock plunged after the FDA rejected Vyglxia for spinocerebellar ataxia, prompting major R&D cuts and a William Bl...

Core News & Articles

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and...

 citigroup-initiates-coverage-on-biohaven-with-buy-rating-announces-price-target-of-28

Citigroup analyst Samantha Semenkow initiates coverage on Biohaven (NYSE:BHVN) with a Buy rating and announces Price Target ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION